DOTATATE
Based on 4 publication(s) in Google Scholar
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 177943-88-3
- Formule: C65H90N14O19S2
- Masse moléculaire:1435.62
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DOTATATE
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
RDC Peptide |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | IC50 |
547 nM
Compound: DOTA-TOCA
|
In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 5 expressed in CHO-K1 cells; (n=3)
In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 5 expressed in CHO-K1 cells; (n=3)
|
[PMID: 15828816] |
| CHO-K1 | IC50 |
>10000 nM
Compound: DOTA-TOCA
|
In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 1 expressed in CHO-K1 cells; (n=3)
In vitro inhibition of [125I][Leu8,D-Trp22,Tyr25] somatostatin 28 binding to human somatostatin receptor type 1 expressed in CHO-K1 cells; (n=3)
|
[PMID: 15828816] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 177943-88-3
-
Appearance Solid
-
Masse moléculaire 1435.62
-
Formule C65H90N14O19S2
-
Color White to off-white
-
Synonyms
Oxodotreotide
-
Sequence
{DOTA}-{d-Phe}-Cys-Tyr-{d-Trp}-Lys-Thr-Cys-Thr (Disulfide bridge:Cys2-Cys7)
-
Sequence Shortening
{DOTA}-{d-Phe}-CY-{d-Trp}-KTCT (Disulfide bridge:Cys2-Cys7)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Nucl Med
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE. [Abstract]2024 Oct 1;65(10):1619-1625. PMID: 39209546
DOTATATE purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Total absorbed dose to cell nucleus for range of added activity concentrations of both 161Tb- and 177Lu-labeled DOTATATE (0-1.25 MBq/mL).
DOTATATE purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Radiolabeled DOTATATE (1 MBq/mL) resulted in a higher absorbed dose than did radiolabeled DOTA-LM3, because of DOTATATE's higher Bmax and higher internalization.
DOTATATE purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
The nuclear dose-response data of both [177Lu]Lu- and [161Tb]Tb-DOTATATE (0-25 Gy) were best fitted with a linear model and could be fitted with a common, single curve.
DOTATATE purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
The saturation binding assay represented total binding and nonspecific binding for different added activity concentrations of [161Tb]Tb-DOTATATE (0-60 nM) with a fixed molar activity of 100 MBq/nmol.
DOTATATE purchased from MedChemExpress. Usage Cited in: J Nucl Med. 2024 Oct 1;65(10):1619-1625. [Abstract]
Clonogenic survival of CA20948 cells after treatment with [161Tb]Tb- and [177Lu]Lu-DOTATATE (0-1.5 MBq/mL) as a function of added activity concentration (MBq/mL).
-
-
-
Solvant et solubilité
DMSO : 100 mg/mL (69.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. [Content Brief]
[2]. Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. [Content Brief]
[3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. [Content Brief]
[4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6966 mL | 3.4828 mL | 6.9656 mL | 17.4141 mL |
| 5 mM | 0.1393 mL | 0.6966 mL | 1.3931 mL | 3.4828 mL | |
| 10 mM | 0.0697 mL | 0.3483 mL | 0.6966 mL | 1.7414 mL | |
| 15 mM | 0.0464 mL | 0.2322 mL | 0.4644 mL | 1.1609 mL | |
| 20 mM | 0.0348 mL | 0.1741 mL | 0.3483 mL | 0.8707 mL | |
| 25 mM | 0.0279 mL | 0.1393 mL | 0.2786 mL | 0.6966 mL | |
| 30 mM | 0.0232 mL | 0.1161 mL | 0.2322 mL | 0.5805 mL | |
| 40 mM | 0.0174 mL | 0.0871 mL | 0.1741 mL | 0.4354 mL | |
| 50 mM | 0.0139 mL | 0.0697 mL | 0.1393 mL | 0.3483 mL | |
| 60 mM | 0.0116 mL | 0.0580 mL | 0.1161 mL | 0.2902 mL |
DOTATATE Related Classifications
HY-106244 Related Classifications
Powered by Bioz